Seven year follow-up of riboflavin/ultraviolet A corneal cross-linking to halt the progression of keratoconus and corneal ectasia

Session Details

Session Title: Cross-Linking

Session Date/Time: Sunday 06/09/2015 | 08:00-09:30

Paper Time: 09:24

Venue: Main Auditorium

First Author: : N.O'Brart UK

Co Author(s): :    D. O'Brart MD FRCS FRCOphth   P. Patel BSc   G. Lascaratos FRCOphth   V. Wagh FRCOphth   C. Tam MCOptom   J. Lee MCOptom     

Abstract Details

Purpose:

To determine long-term efficacy and safety of riboflavin/ultraviolet A corneal cross-linking (CXL).

Setting:

1) Department of Ophthalmology, St. Thomas' Hospital, London,United Kingdom. 2) School of Optometry, University of Cardiff, Cardiff, Wales.

Methods:

Thirty-six patients (36 eyes) who underwent epithelium off CXL at our institution 6-8 years previously were examined.

Results:

At 7 years, mean spherical equivalent refractive error (SEQ) increased by +0.78D (p<0.005),UCDA (p<0.0005), CDVA improved (p<0.0001), mean topographic keratometry (SimK) reduced by 0.74D (p<0.0001), mean maximum keratometry (Kmax) by 0.91D (p<0.0001), compared to preoperatively, with RMS (p<0.0005), coma (p<0.0005) and secondary astigmatism (p<0.005) less. Compared to 1 year, CDVA improved (p<0.05), mean SimK, mean Kmax, RMS and coma decreased (p<0.005). Compared to 5 years, at 7 years CDVA and trefoil reduced (p<0.05), other parameters remained unchanged. No eyes progressed. In 29 untreated fellow eyes astigmatism, mean SimK increased and mean Kmax by (p<0.05).

Conclusions:

CXL is effective and safe with up to 7 year follow-up. Improvements in topographic and wave-front parameters evident at 1 year continue to improve at 5 years and remain stable at 7 years.

Financial Interest:

NONE